MedGenome secures $20M funds from Sequoia Capital. MedGenome is a provider of clinical genomics solutions for personalized healthcare. The company assists doctors and researchers across the globe to develop and tailor made treatments specifically for each patient’s genetic code which is unique.
The company aims to improve global health by developing deep insights into diseases at the genetic and molecular level. MedGenome solutions apply cutting-edge genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large South Asian population to understand genetic basis of cancer, metabolic disorders, eye disorders and other rare diseases. The company also addresses on hereditary diseases, cardiovascular complications and neurological disorders.
MedGenome was incubated by SciGenom Labs, Kochi, India. Later the company was hived into a separate entity. MedGenome shifted their base to Bengaluru, the startup capital of India. MedGenome is headed by Sam Santosh; he has graduated in Bachelor of Technology in Engineering from Government Engineering College, Thrissur in 1984. He went on to do his Masters of Business Administration in MIS from Indian Institute of Management, Calcutta in 1987. He has attended an executive program on preparing humanity for exponential technology space from Singularity University in 2010.
Sam has published several articles in various seminars. Prominent among them are Sequencing and analysis of a South Asian Indian personal genome, Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian Population of Kerala and Evolution of targeted therapies in cancer; opportunities and challenges in the clinic.
After his Masters studies, Sam becomes owner of CAMC in his native in 1988, after running the business for 3 years, in 1992 he became Director, CAD Center, Kochi. He headed this post for close to 13 years. Apart from this position he was President and CEO of Calsoft Labs, Managing Director & CEO of California Software, Independent Director of Accel Frontline Ltd, Board Member for the centre for the commercialization of Antibodies and Biologics, Strategic Advisor for Impelsys, CEO of SciGenom.
Vedam Ramprasad is Chief Operating Officer of MedGenome. He has done Masters and Ph.D. from BITS, Pilani. He has worked as Scientist – Molecular Genetics at Vision Research Foundation, Sankara Nethralaya, Chennai.
MedGenome secured their Series ‘A’ funding during June, 2014 for $4 million from Emerge Education, Papillon Capital and few other investors like ex-President of Bloomberg BNA Legal’s Dmitri Mehlhorn and Co-founder of MuSigma, Ambiga Dhiraj. As part of deal, Emerge Education’s Mahesh Pratapneni and Kartik Kumaramangalam of Papillion Capital joined the board of MedGenome.
The company secured their Series ‘B’ funding in July 2015 for $20 million from Sequoia Capital. The fund valued the company at $70-$80 million. The funds will be utilized for further technology and research developments. MedGenome has developed several single gene tests, disease panels and investigational tests that dwell into Paediatrics, Prenatal, Cardio, Ophthalmology, Nephrology, Haematology, Neurology and few others. The company has the office presence in Kochi, Delhi NCR and Chennai apart from Bengaluru. MedGenome has offices in San Francisco and Cambridge too.